Limiting the use of drug-eluting stents for reducing restenosis after percutaneous coronary intervention saves costs without affecting the rate of death within a year, according to a study published in Circulation.
Researchers studied the clinical impact and cost-effectiveness of using drug-eluting stents at different rates. The use of drug-eluting stents decreased from 92 percent in 2004 to 68 percent in 2007. They found that in this period, although the incidence of target lesion revascularization increased one percent, the rates of death or myocardial infarction within one year did not change. In addition, total cardiovascular costs per patient decreased by $401 from 2004-2007.
The authors concluded that unrestricted use of drug-eluting stents may be a relatively inefficient use of healthcare resources.
Read the abstract in Circulation on drug-eluting stents.
Memorial Hospital of Rhode Island Chooses Brigham and Women's Over Nearby R.I. Hospitals for Cardiac Care
Study: ED Crowding Doesn't Delay Heart Attack Treatment Start Time
Researchers studied the clinical impact and cost-effectiveness of using drug-eluting stents at different rates. The use of drug-eluting stents decreased from 92 percent in 2004 to 68 percent in 2007. They found that in this period, although the incidence of target lesion revascularization increased one percent, the rates of death or myocardial infarction within one year did not change. In addition, total cardiovascular costs per patient decreased by $401 from 2004-2007.
The authors concluded that unrestricted use of drug-eluting stents may be a relatively inefficient use of healthcare resources.
Read the abstract in Circulation on drug-eluting stents.
Related Articles on Hospital Cardiology:
Maui Memorial Medical Center Begins Cardiology ProgramMemorial Hospital of Rhode Island Chooses Brigham and Women's Over Nearby R.I. Hospitals for Cardiac Care
Study: ED Crowding Doesn't Delay Heart Attack Treatment Start Time